NZ610729A - Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate - Google Patents

Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Info

Publication number
NZ610729A
NZ610729A NZ610729A NZ61072911A NZ610729A NZ 610729 A NZ610729 A NZ 610729A NZ 610729 A NZ610729 A NZ 610729A NZ 61072911 A NZ61072911 A NZ 61072911A NZ 610729 A NZ610729 A NZ 610729A
Authority
NZ
New Zealand
Prior art keywords
tenofovir disoproxil
disoproxil fumarate
rilpivirine hcl
therapeutic compositions
layer
Prior art date
Application number
NZ610729A
Other languages
English (en)
Inventor
Reza Oliyai
Lauren Wiser
Mark Menning
Original Assignee
Gilead Sciences Inc
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ610729(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc, Janssen Sciences Ireland Uc filed Critical Gilead Sciences Inc
Publication of NZ610729A publication Critical patent/NZ610729A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ610729A 2010-11-19 2011-11-18 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate NZ610729A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19
PCT/US2011/061515 WO2012068535A1 (en) 2010-11-19 2011-11-18 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Publications (1)

Publication Number Publication Date
NZ610729A true NZ610729A (en) 2015-10-30

Family

ID=45094284

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ610729A NZ610729A (en) 2010-11-19 2011-11-18 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Country Status (36)

Country Link
US (1) US10857102B2 (enExample)
EP (2) EP2826466A1 (enExample)
JP (2) JP2014500261A (enExample)
KR (1) KR101923103B1 (enExample)
CN (2) CN103491948B (enExample)
AP (1) AP3816A (enExample)
AR (2) AR084500A1 (enExample)
AU (3) AU2011329642B2 (enExample)
BR (1) BR112013012245B1 (enExample)
CA (1) CA2818097C (enExample)
CL (1) CL2013001402A1 (enExample)
CO (1) CO6761300A2 (enExample)
CR (1) CR20130293A (enExample)
DK (1) DK2640362T4 (enExample)
EA (2) EA201691695A1 (enExample)
EC (2) ECSP13012700A (enExample)
ES (1) ES2524408T5 (enExample)
HK (1) HK1206592A1 (enExample)
HR (1) HRP20140946T1 (enExample)
IL (1) IL226300B (enExample)
MA (1) MA34735B1 (enExample)
ME (1) ME01980B (enExample)
MX (1) MX347512B (enExample)
MY (1) MY185604A (enExample)
NZ (1) NZ610729A (enExample)
PE (3) PE20211657A1 (enExample)
PH (1) PH12013501002A1 (enExample)
PL (1) PL2640362T5 (enExample)
PT (1) PT2640362E (enExample)
RS (1) RS53691B1 (enExample)
SG (3) SG10201509521WA (enExample)
SM (1) SMT201400150B (enExample)
TW (1) TWI556840B (enExample)
UA (1) UA114075C2 (enExample)
WO (1) WO2012068535A1 (enExample)
ZA (1) ZA201304481B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4996241B2 (ja) 2003-01-14 2012-08-08 ギリアード サイエンシーズ， インコーポレイテッド 組み合わせ抗ウイルス治療のための組成物および方法
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EA201691695A1 (ru) 2010-11-19 2017-11-30 Джилид Сайэнс, Инк. Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат
DK2744810T4 (da) 2011-08-16 2023-11-20 Gilead Sciences Inc Tenofovir-alafenamid-hemifumarat
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
MX344879B (es) 2012-12-21 2017-01-11 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
EP2832351A1 (en) * 2013-07-29 2015-02-04 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
LT3236972T (lt) 2014-12-26 2021-11-10 Emory University Antivirusiniai n4-hidroksicitidino dariniai
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
KR102606625B1 (ko) 2015-11-09 2023-11-27 길리애드 사이언시즈, 인코포레이티드 인간 면역결핍 바이러스의 치료를 위한 치료 조성물
WO2017175855A1 (en) * 2016-04-08 2017-10-12 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
RU2755710C2 (ru) * 2017-06-30 2021-09-20 Вайв Хелткер Компани Комбинация, ее применение и способы лечения с использованием указанной комбинации
LT3706762T (lt) 2017-12-07 2024-12-27 Emory University N4-hidroksicitidinas ir jo dariniai bei susiję naudojimo prieš virusus būdai
CN114126655A (zh) * 2019-07-03 2022-03-01 爱尔兰詹森科学公司 用利匹韦林治疗儿科患者的hiv的方法
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺
WO2024211882A1 (en) * 2023-04-07 2024-10-10 Navinta, Llc Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN119174735A (zh) * 2024-09-03 2024-12-24 安徽贝克生物制药有限公司 一种含利匹韦林的复方片及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AU2002359518A1 (en) 2001-11-27 2003-06-10 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
JP4996241B2 (ja) 2003-01-14 2012-08-08 ギリアード サイエンシーズ， インコーポレイテッド 組み合わせ抗ウイルス治療のための組成物および方法
CN104586850A (zh) 2004-09-02 2015-05-06 詹森药业有限公司 4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的盐酸盐
PL1632232T6 (pl) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2007047371A2 (en) 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination
ATE474560T1 (de) 2005-12-14 2010-08-15 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
EP2118082B1 (en) * 2007-02-23 2014-10-01 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
CN101778855A (zh) * 2007-05-22 2010-07-14 阿尔迪默菲克斯技术有限责任公司 替诺福韦酯半富马酸共晶体
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
AP3089A (en) 2008-05-02 2015-01-31 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
BRPI1008664A2 (pt) 2009-02-06 2016-03-08 Gilead Sciences Inc comprimidos para a terapia de combinação
MX352646B (es) 2009-09-21 2017-12-04 Gilead Sciences Inc Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral.
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
EA201691695A1 (ru) 2010-11-19 2017-11-30 Джилид Сайэнс, Инк. Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат

Also Published As

Publication number Publication date
AU2011329642A1 (en) 2013-05-02
HK1206592A1 (en) 2016-01-15
TW201238612A (en) 2012-10-01
MX347512B (es) 2017-04-28
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
SG10201509521WA (en) 2015-12-30
CN103491948B (zh) 2016-11-02
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
PH12013501002A1 (en) 2013-09-09
EA201390651A1 (ru) 2013-11-29
AU2016208417B2 (en) 2018-04-05
AP3816A (en) 2016-09-30
MY185604A (en) 2021-05-25
EA201691695A1 (ru) 2017-11-30
DK2640362T3 (en) 2014-12-01
CN103491948A (zh) 2014-01-01
AR084500A1 (es) 2013-05-22
EA025852B1 (ru) 2017-02-28
CR20130293A (es) 2013-10-03
US10857102B2 (en) 2020-12-08
PL2640362T5 (pl) 2022-05-02
EP2640362B2 (en) 2021-12-01
JP2015131853A (ja) 2015-07-23
AR123409A2 (es) 2022-11-30
KR20140037799A (ko) 2014-03-27
EP2640362A1 (en) 2013-09-25
ES2524408T3 (es) 2014-12-09
CL2013001402A1 (es) 2013-12-27
MX2013005669A (es) 2013-11-04
PT2640362E (pt) 2014-11-28
JP6138851B2 (ja) 2017-05-31
EP2826466A1 (en) 2015-01-21
HRP20140946T1 (hr) 2015-02-13
CA2818097A1 (en) 2012-05-24
IL226300B (en) 2019-05-30
AP2013006931A0 (en) 2013-06-30
SMT201400150B (it) 2015-01-15
RS53691B1 (sr) 2015-04-30
WO2012068535A1 (en) 2012-05-24
EP2640362B1 (en) 2014-09-10
PE20170521A1 (es) 2017-05-27
CA2818097C (en) 2019-07-30
AU2018202635A1 (en) 2018-05-10
ECSP13012700A (es) 2013-08-30
BR112013012245B1 (pt) 2022-09-27
ZA201304481B (en) 2022-03-30
CO6761300A2 (es) 2013-09-30
TWI556840B (zh) 2016-11-11
JP2014500261A (ja) 2014-01-09
HK1190064A1 (en) 2014-06-27
PE20211657A1 (es) 2021-08-24
PL2640362T3 (pl) 2015-03-31
MA34735B1 (fr) 2013-12-03
SG190333A1 (en) 2013-06-28
UA114075C2 (xx) 2017-04-25
ME01980B (me) 2015-05-20
PE20140163A1 (es) 2014-02-08
US20130243857A1 (en) 2013-09-19
ES2524408T5 (es) 2022-04-25
BR112013012245A2 (pt) 2016-08-09
KR101923103B1 (ko) 2018-11-28
SG10201912527XA (en) 2020-02-27
AU2016208417A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
NZ610729A (en) Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
MX366159B (es) Liberacion autorregulada de ingrediente farmaceutico activo.
MY178634A (en) Topical formulation for a jak inhibitor
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
NZ595046A (en) Compositions and methods for extended therapy with aminopyridines
MX347101B (es) Forma de dosis de disolucion rapida de vacuna oral que usa almidon.
WO2014007972A3 (en) Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
MX2014012799A (es) Tabletas recubiertas y la produccion de las mismas.
MX2011010359A (es) Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
MX347805B (es) Peptidos del factor viii (fviii) para la induccion de tolerancia inmune y para inmunodiagnostico.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
MX2016002560A (es) Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
WO2014027979A3 (en) Tablet formulations comprising tadalafil and dapoxetine
PH12014501352A1 (en) Non-enteric pharmaceutical composition comprising crofelemer
IN2013CH05288A (enExample)
IN2012CH05549A (enExample)
TH171908A (th) องค์ประกอบบำบัดที่ประกอบรวมด้วย ริลพิวิรีน HCL (rilpivirine HCL) และ เทโนโฟเวียร์ ไดโซพรอกซิล ฟิวมาเรต (tenofovir disoproxil fumarate)
NZ612095A (en) Improved tolerance in a low calorie infant formula
UA57852U (ru) Способ лечения рецидивных форм аллергодерматозов у больных c наличием вторичных иммунодефицитных состояний
MX355000B (es) Composición farmacéutica en microesferas con antihistamínico no sedante y antiemético.
NZ726034A (en) Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
CN302312726S (zh) 卧房椅(一)
CN302465442S (zh) 药盒(止痛化癥)

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: GILEAD SCIENCES, INC., US

Effective date: 20150917

Owner name: JANSSEN SCIENCES IRELAND UC, IE

Effective date: 20150917

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 NOV 2018 BY DAVIES COLLISON CAVE

Effective date: 20160203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2019 BY COMPUTER PACKAGES INC

Effective date: 20181031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2020 BY COMPUTER PACKAGES INC

Effective date: 20191031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2021 BY CPA GLOBAL

Effective date: 20201001

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2022 BY CPA GLOBAL

Effective date: 20211008

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2023 BY CPA GLOBAL

Effective date: 20221007

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2024 BY CPA GLOBAL

Effective date: 20231006

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241003

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 NOV 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251002